A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Regorafenib
Related studies linked through entity extraction aliases.
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
- Status
- RECRUITING
- Phase
- PHASE2
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
- Status
- UNKNOWN
- Phase
- N/A
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
- Status
- TERMINATED
- Phase
- PHASE3
RegoNivo vs Standard of Care Chemotherapy in AGOC
- Status
- COMPLETED
- Phase
- PHASE3
Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib
- Status
- COMPLETED
- Phase
- PHASE4
PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
- Status
- COMPLETED
- Phase
- PHASE3
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
- Status
- UNKNOWN
- Phase
- N/A
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC
- Status
- UNKNOWN
- Phase
- PHASE2
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
- Status
- UNKNOWN
- Phase
- N/A
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
- Status
- TERMINATED
- Phase
- PHASE2
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2